AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

4,919.00p
   
  • Change Today:
    -40.50p
  • 52 Week High: 5,220.00
  • 52 Week Low: 3,774.00
  • Currency: UK Pounds
  • Shares Issued: 1,265.39m
  • Volume: 301,528
  • Market Cap: 62,244m
  • RiskGrade: 95
  • Beta: 0.50

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 4.5% 4.5%
Div Cover 1.5 1.3
Op Mrgn 23.0% 25.1%
ROCE n/a  
Latest F'cast
P/E 14.4 16.6
PEG 12.3 n/a
Pr/Revenue 3.7 3.6
Pr/Book 4.7  
Latest F'cast
Revenue -9.8% -35.4%
PBT 15.7% -2.7%
EPS 1.2% -14.2%
DPS n/a -36.4%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 27,973.00 7,646.00 683.00¢ 5.3 n/a -6% 280.00¢ 7.7%
31-Dec-13 25,711.00 3,267.00 505.00¢ 8.8 n/a -26% 280.00¢ 6.3%
31-Dec-14 26,095.00 1,246.00 428.00¢ 13.3 n/a -15% 280.00¢ 4.9%
31-Dec-15 23,641.00 3,069.00 426.00¢ 13.5 n/a -0% 280.00¢ 4.9%
31-Dec-16 21,319.00 3,552.00 431.00¢ 12.9 12.9 +1% 280.00¢ 5.1%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 17,212.07 4,317.04 298.56p 16.6 n/a -14% 222.49p 4.5%
31-Dec-18 17,757.21 4,437.33 322.82p 15.4 1.9 +8% 225.84p 4.6%

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

US FDA issues CRL for ZS-9 in hyperkalaemia 17-Mar-2017 07:00 RNS
Notice of AGM 16-Mar-2017 11:00 RNS
LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY 15-Mar-2017 07:00 RNS

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 4,919.00p
Change Today -40.50p
% Change -0.82 %
52 Week High 5,220.00
52 Week Low 3,774.00
Volume 301,528
Shares Issued 1,265.39m
Market Cap 62,244m
Beta 0.50
RiskGrade 95

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
52.42% below the market average52.42% below the market average52.42% below the market average52.42% below the market average52.42% below the market average
46.67% above the sector average46.67% above the sector average46.67% above the sector average46.67% above the sector average46.67% above the sector average
Price Trend
7.66% above the market average7.66% above the market average7.66% above the market average7.66% above the market average7.66% above the market average
29.03% above the sector average29.03% above the sector average29.03% above the sector average29.03% above the sector average29.03% above the sector average
Income
69.30% above the market average69.30% above the market average69.30% above the market average69.30% above the market average69.30% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Growth
53.22% below the market average53.22% below the market average53.22% below the market average53.22% below the market average53.22% below the market average
69.57% below the sector average69.57% below the sector average69.57% below the sector average69.57% below the sector average69.57% below the sector average

What The Brokers Say

Strong Buy 22
Buy 3
Neutral 11
Sell 0
Strong Sell 3
Total 39
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 16-Feb-17 11-Aug-16
Paid 20-Mar-17 12-Sep-16
Amount 190.00¢ 90.00¢

Trades for 24-Mar-2017

Time Volume / Share Price
09:58 116 @ 4,919.00p
09:58 72 @ 4,917.00p
09:58 139 @ 4,917.00p
09:58 155 @ 4,916.50p
09:58 137 @ 4,916.50p

Top of Page